JP2011162556A5 - - Google Patents

Download PDF

Info

Publication number
JP2011162556A5
JP2011162556A5 JP2011109756A JP2011109756A JP2011162556A5 JP 2011162556 A5 JP2011162556 A5 JP 2011162556A5 JP 2011109756 A JP2011109756 A JP 2011109756A JP 2011109756 A JP2011109756 A JP 2011109756A JP 2011162556 A5 JP2011162556 A5 JP 2011162556A5
Authority
JP
Japan
Prior art keywords
compound
medicament
ion
disease
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011109756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011162556A (ja
JP5450509B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011162556A publication Critical patent/JP2011162556A/ja
Publication of JP2011162556A5 publication Critical patent/JP2011162556A5/ja
Application granted granted Critical
Publication of JP5450509B2 publication Critical patent/JP5450509B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011109756A 2003-10-14 2011-05-16 ムスカリン性アセチルコリン受容体アンタゴニスト Expired - Fee Related JP5450509B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51100903P 2003-10-14 2003-10-14
US60/511,009 2003-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007201718A Division JP4796552B2 (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト

Publications (3)

Publication Number Publication Date
JP2011162556A JP2011162556A (ja) 2011-08-25
JP2011162556A5 true JP2011162556A5 (enExample) 2012-08-09
JP5450509B2 JP5450509B2 (ja) 2014-03-26

Family

ID=34465175

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006535591A Pending JP2007508390A (ja) 2003-10-14 2004-10-12 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201718A Expired - Fee Related JP4796552B2 (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201719A Pending JP2007314567A (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2011109756A Expired - Fee Related JP5450509B2 (ja) 2003-10-14 2011-05-16 ムスカリン性アセチルコリン受容体アンタゴニスト

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2006535591A Pending JP2007508390A (ja) 2003-10-14 2004-10-12 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201718A Expired - Fee Related JP4796552B2 (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201719A Pending JP2007314567A (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト

Country Status (34)

Country Link
US (3) US7276521B2 (enExample)
EP (1) EP1677795B1 (enExample)
JP (4) JP2007508390A (enExample)
KR (3) KR20080065318A (enExample)
CN (3) CN1893948A (enExample)
AP (3) AP2007004238A0 (enExample)
AR (1) AR046103A1 (enExample)
AT (1) ATE494285T1 (enExample)
AU (1) AU2004281724B2 (enExample)
BR (1) BRPI0415361A (enExample)
CA (1) CA2542657C (enExample)
CY (1) CY1111364T1 (enExample)
DE (1) DE602004030930D1 (enExample)
DK (1) DK1677795T3 (enExample)
EA (3) EA009899B1 (enExample)
EC (1) ECSP066468A (enExample)
ES (1) ES2358673T3 (enExample)
HR (1) HRP20110232T1 (enExample)
IL (2) IL174843A0 (enExample)
IS (1) IS2918B (enExample)
MA (1) MA28110A1 (enExample)
MX (1) MXPA06004244A (enExample)
MY (1) MY143366A (enExample)
NO (1) NO20062042L (enExample)
NZ (2) NZ556424A (enExample)
OA (1) OA13316A (enExample)
PE (1) PE20050963A1 (enExample)
PL (1) PL1677795T3 (enExample)
PT (1) PT1677795E (enExample)
SG (1) SG147436A1 (enExample)
SI (1) SI1677795T1 (enExample)
TW (3) TW200811172A (enExample)
UA (2) UA89734C2 (enExample)
WO (1) WO2005037280A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050963A1 (es) * 2003-10-14 2006-01-11 Glaxo Group Ltd Compuestos derivados de 8-azoniabiciclo [3.2.1]octanos como antagonistas de receptores de acetilcolina muscarinicos
AP2006003575A0 (en) * 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ グループ リミテッド M3ムスカリン性アセチルコリン受容体アンタゴニスト
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド M3ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
AR060536A1 (es) 2006-04-20 2008-06-25 Glaxo Group Ltd Agonista del receptor de glucocorticoides y composiciones farmaceuticas
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
HRP20110434T1 (hr) 2006-08-01 2011-08-31 Glaxo Group Limited Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4
ATE547394T1 (de) * 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EP2197444A1 (en) * 2007-09-12 2010-06-23 Glaxo Group Limited Novel combination of therapeutic agents
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Pi3キナーゼの阻害剤として有用な4−カルボキサミドインダゾール誘導体
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ikk2阻害剤としてのインドール誘導体
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Itk阻害剤として使用されるピリミジン誘導体
TWI516487B (zh) 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN116194114A (zh) 2020-03-26 2023-05-30 葛兰素史密斯克莱知识产权发展有限公司 用于防止或治疗病毒感染的组织蛋白酶抑制剂

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800482A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9000304D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Muscarinic receptor antagonists
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH08291141A (ja) * 1995-04-21 1996-11-05 Kotobuki Seiyaku Kk ジフェニル酢酸誘導体及びその製造法
JPH0920758A (ja) * 1995-07-06 1997-01-21 Kyorin Pharmaceut Co Ltd 新規環状ジアミン誘導体及びその製造法
US6350758B1 (en) 1996-12-02 2002-02-26 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PL370087A1 (en) * 2001-10-17 2005-05-16 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
DE10211700A1 (de) * 2002-03-16 2003-09-25 Boehringer Ingelheim Pharma Neue Difurylglykolsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
EP1613307A4 (en) 2003-04-07 2008-03-12 Glaxo Group Ltd M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UY28417A1 (es) 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050963A1 (es) * 2003-10-14 2006-01-11 Glaxo Group Ltd Compuestos derivados de 8-azoniabiciclo [3.2.1]octanos como antagonistas de receptores de acetilcolina muscarinicos
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1827439A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド M3ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937068A4 (en) 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS

Similar Documents

Publication Publication Date Title
JP2011162556A5 (enExample)
HRP20110232T1 (hr) Antagonisti muskarinskog acetilkolinskog receptora
JP2013542940A5 (enExample)
HRP20120775T1 (hr) Antagonisti m3 muskarinskog acetilkolinskog receptora
HRP20120832T1 (hr) Antagonisti muskarinskih acetilkolinskih receptora
JP2013531056A5 (enExample)
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
US20100329996A1 (en) Novel Combination of Therapeutic Agents
JP2014515351A5 (enExample)
ES2759247T3 (es) Antagonistas muscarínicos y combinaciones de estos para el tratamiento de enfermedades de las vías respiratorias en caballos
PT2506844T (pt) Combinações de um antagonista do recetor muscarínico e um agonista do adrenorrecetor beta-2
JP2016527220A5 (enExample)
JP2015519356A5 (enExample)
JP2007520508A5 (enExample)
RU2608713C3 (ru) Новая доза и препаративная форма
JP2016534088A5 (enExample)
RU2006104854A (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
RU2006129289A (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
RU2006104851A (ru) Антагонисты мускариновых рецепторов ацетилхолина
JP2007522141A5 (enExample)
JP2015503579A5 (enExample)
JP2008531558A5 (enExample)
JP2012532191A5 (enExample)
JP2014511897A5 (enExample)
JP2014518894A (ja) ウメクリジニウムを含む乾燥粉末インヘラー組成物